Skip to content

Aprea Therapeutics Announces Presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco

BOSTON and STOCKHOLM, Jan. 7, 2019 /PRNewswire/ — Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S. Schade, President & Chief Executive Officer, is scheduled to present a company update and overview at the 37th Annual J.P. Morgan Healthcare Conference at 11:30a.m. PT on Tuesday, January 8, 2019 at the Westin St. Francis Hotel in San Francisco, CA.


About Aprea Therapeutics

Aprea Therapeutics is a Boston, Massachusetts and Stockholm, Sweden based biopharmaceutical company focused on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The Company has commenced a Phase 3 clinical study in myelodysplastic syndrome (MDS) with its lead drug candidate APR-246, a first-in-class small molecule.  Aprea is planning additional clinical studies in hematological malignancies in addition to its solid tumor studies.  Aprea is also developing second generation p53 reactivators that have best-in-class potential.  In November 2018, Aprea completed a EUR 50 million Series C financing with an international syndicate led by the Redmile Group, with participation by new investor Rock Springs Capital and existing investors 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB (Nasdaq Stockholm: KDEV). For more information, please visit

About p53 and APR-246

The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors.  These mutations are often associated with resistance to anti-cancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer.

APR-246 has been shown to reactivate mutant and inactivated p53 protein – by restoring wild-type p53 conformation and function – and thereby induce programmed cell death in human cancer cells.  APR-246 has demonstrated pre-clinical anti-tumor activity in a wide variety of solid and hematological (blood) tumors, including MDS, AML, and ovarian cancer, among others.  Additionally, strong synergy has been seen with both traditional anti-cancer agents, such as chemotherapy, as well as newer mechanism-based anti-cancer drugs and immuno-oncology checkpoint inhibitors. In addition to pre-clinical testing, a Phase I/II clinical program with APR-246 has been completed, demonstrating a favorable safety profile and both biological and confirmed clinical responses in hematological malignancies and solid tumors with mutations in the TP53 gene.

Corporate Contacts:

Christian S. Schade
President and Chief Executive Officer


Gregory A. Korbel
Vice President of Business Development

Source: PRNewswireAprea